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Kruskal–Wallis testMicrosomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors are considered as potential therapeutic
agents for the treatment of inﬂammatory pain and certain types of cancer. So far, several series of acidic
as well as non-acidic inhibitors of mPGES-1 have been discovered. Acidic inhibitors, however, may have
issues, such as loss of potency in human whole blood and in vivo, stressing the importance of the design
and identiﬁcation of novel, non-acidic chemical scaffolds of mPGES-1 inhibitors. Using a multistep virtual
screening protocol, the Vitas-M compound library (1.3 million entries) was ﬁltered and 16 predicted
compounds were experimentally evaluated in a biological assay in vitro. This approach yielded two
molecules active in the low micromolar range (IC50 values: 4.5 and 3.8 lM, respectively).
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In the arachidonic acid cascade, the activity of the cytosolic
phospholipase A2 is required for the release of arachidonic acid
(AA), a critical precursor molecule for pro-inﬂammatory mediators.
Different enzymatic pathways convert AA into distinct eicosanoids.
These mediators regulate various physiological processes and also
trigger multiple effects in various human diseases.1,2 Among these
mediators, prostaglandin E2 (PGE2) is well recognized as critical
bioactive molecule. High PGE2 levels, typically occurring in inﬂam-
mation, are relevant for swelling, fever, and inﬂammatory pain,
and thus, pharmacological inhibition of PGE2 biosynthesis is con-
sidered a promising opportunity for the treatment of inﬂammatory
pain, for example, in rheumatic diseases.3 Additionally, PGE2 syn-
thesis is important in tumor growth and cancer progression.4–6
PGE2 is produced from the cyclooxygenase (COX)-derived prosta-
glandin H2 (PGH2) by PGE2 synthases (PGES) (EC 5.3.99.3).7
Among the three PGES isoenzymes, the microsomal PGES-1
(mPGES-1) displays a unique role because its expression is induced
in the inﬂammatory response, similar to COX-2.8
By inhibiting mPGES-1 as the terminal synthase in PGE2
biosynthesis, mPGES-1 inhibitors are considered very promising
regarding their side effect proﬁle.9,10 The application of other
anti-inﬂammatory agents, such as unspeciﬁc COX inhibitors,traditional nonsteroidal anti-inﬂammatory drugs (NSAIDs), or
COX-2-selective inhibitors (coxibs), is associated with side effects
concerning, among others, the renal function and effects on the
gastrointestinal tract.11 In contrast, during prolonged inhibition
of mPGES-1 in dogs, pronounced effects on the renal function were
not observed.12 So far, there is no mPGES-1 inhibitor available for
clinical use, although data from pre-clinical studies stressed the
relevance of mPGES-1 inhibitors as potentially therapeutic agents.
Therefore, the development of mPGES-1 inhibitors is highly
relevant.13
A series of mPGES-1 inhibitors is reported in the literature, of
which several comprise an acidic functionality, such as an oxicam
template,14 a sulfonamide group15 or a carboxylic acid moiety.16,17
Unfortunately, acidic molecules suppressing mPGES-1 activity may
have inferior potency in human whole blood seemingly due to
unspeciﬁc plasma protein binding.14,16 This suggests that the
design and identiﬁcation of novel, non-acidic chemical scaffolds
is warranted. As an overview, non-acidic chemical scaffolds of
mPGES-1 inhibitors, which were reported so far, are shown in
Figure 1.18–27
Previously, we reported the discovery of acidic mPGES-1 inhibi-
tors using a pharmacophore-based virtual screening approach.
Using this screening protocol, acidic inhibitors from synthetic
libraries were discovered. The most potent inhibitors exhibited
IC50 values in the sub-micromolar range.17 Additionally, mPGES-1
inhibitors with comparable potency from Lichen species were dis-
covered using the previously reported pharmacophore model.28
Figure 1. Chemical series of non-acidic mPGES-1 inhibitors are depicted with 2D structures.
Figure 2. Overview of the virtual screening protocol.
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approaches to ﬁnd novel mPGES-1 inhibitors. For instance,
Rörsch et al. applied a multistep ligand-based virtual screening
protocol to discover novel and non-acidic mPGES-1 inhibitors.29
In addition, several active compounds were discovered by applying
docking-based screening strategies, of which some even elicited
high potency.30–33 Docking-based virtual screening campaigns
towards mPGES-1 have been facilitated as a 3D electron crystallog-
raphy structure was reported in 2008.34 In 2013, a high-resolution
X-ray crystal structure of mPGES-1 has been resolved.35 Very
recently an X-ray crystal structure of mPGES-1 with a co-crystal-
lized ligand has been reported.36
In this study, a novel concept for the validation of the 3D phar-
macophore model was applied using the Kruskal–Wallis test.37
This test was suggested as a robust investigation of the discrimina-
tory power of distinct virtual screening methods, and was previ-
ously used for the comparative assessment of docking and
scoring functions.38,39 The analysis with the Kruskal–Wallis test
is characterized as less artifact-prone and also enables a post hoc
test, rendering this analysis an attractive method in the validation
also for pharmacophore-based virtual screening.38,39
2. Materials and methods
2.1. Study design
In brief, we consecutively performed forward ﬁltering, using
2D similarity screening, and pharmacophore-based virtual
screening. The most interesting molecules which were retained
thereof, accounting in addition pharmacophore ﬁt evaluation
and diversity clustering, were submitted to molecular docking.
Finally, this protocol was applied to prospective virtual screening
of the Vitas-M library (http://www.vitasmlab.com/). The hit-list
was visually inspected to select compounds for a biological eval-
uation to discover novel and non-acidic mPGES-1 inhibitors
(Fig. 2).2.2. Software speciﬁcations
The computational studies were performed on a workstation
running Microsoft Windows 7, which was employed for the work
with the molecular modeling package Discovery Studio version
3.540 and PipelinePilot 8.0.1.41 In parallel, the calculations for the
work with Maestro suite 9.2.11242 were performed on a worksta-
tion running OpenSuse 12.1. The statistical evaluation was per-
formed within Microsoft Excel 2010 and its add-in Analyse-it
Method Evaluation version 2.26.43
2.3. Validation
2.3.1. Concept
We assessed the discriminatory power of the 3D pharma-
cophore model by following the workﬂow reported by Seifert
et al.38,39 In this work, the discriminatory power of docking and
scoring functions was assessed by ANOVA (analysis of variance)
or a nonparametric version of it, that is, the Kruskal–Wallis test.37
Because this concept can also be useful for the development of 3D
pharmacophore models, this analysis was included in the model
validation and conducted as an extension to the validation with
benchmarking experiments. So a validation set, set_1, was assem-
bled and used for screening experiments with the hypotheses. The
S. M. Noha et al. / Bioorg. Med. Chem. 23 (2015) 4839–4845 4841statistical evaluation of the results was accomplished with the
Kruskal–Wallis test and a post hoc test. Furthermore, benchmark-
ing experiments were conducted by screening a second validation
set, set_2, and calculating well-established performance metrics.
2.3.2. Validation sets and calculations
Set_1 comprised highly active (IC50 60.5 lM), medium active
(IC50: 0.5–5 lM), and conﬁrmed inactive molecules (IC50 >5 lM)
from several congeneric series of non-acidic mPGES-1 inhibitors,
with 14 molecules in each group. It consisted, in total, of 42 mole-
cules. For more details on set_1, see Supporting information. In the
validation, we screened set_1, followed by the statistical evalua-
tion of the results obtained thereof with the Kruskal–Wallis test.
Furthermore, we included in this analysis Bonferroni’s post hoc
test, employing the conﬁrmed inactive molecules in the post hoc
test as control group, and accounting the results of this evaluation
signiﬁcant with p <0.1.
Additionally, we assembled set_2 by combining highly active
and medium active inhibitors of set_1, resulting in 28 active mole-
cules, and a virtual library of 12,775 putatively inactive molecules
(‘decoys’).44,45 Afterwards, the virtual screening results from set_2
were used to calculate the percent yield (%Y) and the goodness of
hit-list (GH)-score, which follow Eqs. 1 and 2. Furthermore, the
enrichment factor (EF, Eq. 3) was calculated to compare the enrich-
ment in the x% of the ranked hit-list to the ratio of actives to decoys
in the entire validation set. We calculated the EF1% and the EF0.5%
which may attain a maximal value of 100 or 200, respectively.46
%Y ¼ TP
n
 100 ð1Þ
GH ¼ TP  ð3Aþ nÞ
4nA
 
 1 n TP
N  A
 
ð2Þ
EFx% ¼ TPx%=nx%A=N ð3Þ
TP true positives, active molecules retained in the hit-list.
n number of hits found by the method.
A actives, all active molecules.
N all molecules, active molecules and the decoy set.
2.4. Forward ﬁltering
First, to evaluate the enrichment obtained by employing 2D
similarity screening, set_2 was utilized for virtual screening with
2D ﬁngerprints. Later, in prospective virtual library screening 2D
ﬁngerprints were applied with adjusted and optimized settings
and further ﬁlters: (i) a ﬁlter to focus on molecules with aqueous
solubility level P2, and (ii) Veber rules47 and Lipinski’s Rule-of-
5.48 These ﬁlters were applied by performing respective protocols
(‘ADMET Descriptors’ and ‘Filter by Lipinski and Veber Rules’) with
default settings within PipelinePilot, while 2D similarity screening
was performed within Discovery Studio with the protocol ‘Find
Similar Molecules by Fingerprints’. The 2D similarity screening
was performed with SciTegic ﬁngerprints, representing a type of
combinatorial/circular ﬁngerprints.49,50 In the virtual screening
campaign, the Vitas-M library was ﬁltered which was downloaded
in version September 2013 (http://www.vitasmlab.com/,
1,305,485 entries).
2.5. Conformational analysis
Prior to the hypotheses generation process, the conformational
model of the training set compounds was generated usingDiscovery Studio with the more exhaustive ‘BEST’ quality51 and a
maximum number of 255 conformations per molecule.
All compound libraries used for validating the pharmacophore
models and in the prospective virtual library screening were con-
verted into 3D multi-conformational databases using ‘CAESER’
quality52 with a maximum number of 100 conformations per
molecule.
2.6. Pharmacophore modeling and virtual screening
The 3D pharmacophore models were generated employing the
HipHop algorithm within Discovery Studio, which is available as
protocol ‘Common Feature Pharmacophore Generation’. This algo-
rithm elucidates the pharmacophore hypotheses in a so-called
‘pruned exhaustive search’. All two feature hypotheses, which are
feasible in 3D space and are deﬁned by the molecules in the train-
ing set as well as respective conformers as input, are generated.
This is followed by the generation of more complex models utiliz-
ing the hypotheses retrieved in the previous step. The procedure is
stopped when the generation process is exhausted, and then the
best-ranked hypotheses are reported.53,54 Before hypotheses are
created in a running, so-called principal values have to be assigned,
to imply the inﬂuence a training set molecule has on the hypothe-
sis generation process. Furthermore, the value for ‘Maximum
Omitted Features’ (MOF) of a training set compound may be
adjusted; when the value is set to 1, this implies that a ‘partial
ﬁt’ of this training set molecule is allowed. Additionally, the chem-
ical feature types used for model building were set to include
hydrogen-bond donor (HBD), hydrogen-bond acceptor (HBA),
hydrophobic interaction (HYD), aromatic ring (RA), hydrophobic
aromatic, and hydrophobic aliphatic (Hal).
Furthermore, pharmacophore-based virtual screening was per-
formed by applying the ‘best ﬂexible search’ algorithm. In this
algorithm, the database entries are pre-ﬁltered according to the
absence or presence of all required chemical features needed for
pharmacophore ﬁtting in a rapid procedure. This is followed by a
more rigorous procedure attempting to match the atoms of the
3D database molecule conformations to the features of the 3D
search query. During the latter, small modiﬁcations of molecule’s
conformation are allowed to enable and optimize the ﬁtting of
the molecule into the model. As limit for the optimized ﬁtting into
the model, the molecule’s strain energy is accounted during this
procedure.55
2.7. Diversity clustering
To enhance the chemical diversity among the ﬁtting molecules,
diversity clustering was performed within Discovery Studio by
applying the protocol ‘Cluster Ligands’ and using default settings
to return 500 clusters. We collected the ‘cluster centers’ and sub-
mitted these compounds to molecular docking.
2.8. Molecular docking
Docking in the context of prospective virtual library screening
was conducted employing Glide within the graphical interface,
the Maestro suite, and as described previously.56 Following the
preparation of the protein and the organic molecules, molecular
docking was performed and hit-list ranking was achieved employ-
ing Glide in ‘standard precision’ (SP) mode.
For the binding pose predictions, the recently reported X-ray
crystal structure of mPGES-1 with the co-crystallized ligand (PDB
code: LVJ; PDB accession code: 4bpm)36 was utilized for the dock-
ing study. The macromolecule 3D coordinates were downloaded
from the PDBe57 providing a web portal (http://www.ebi.ac.uk/
pdbe/). We employed LigandScout58 to deduce critical molecular
Table 1
Training set for HipHop model
Compound IC50 (lM) Class Reference
1 0.0091 Highly active 26
2 0.25 Active 26
3 0.1 Active 20
4 0.13 Active 25
5 0.4 Active 60
4842 S. M. Noha et al. / Bioorg. Med. Chem. 23 (2015) 4839–4845interactions as 3D pharmacophore as well as for visualization
purposes.
2.9. Induction of mPGES-1 in A549 cells, isolation of
microsomes, and determination of mPGES-1 activity
Human A549 cells were treated and prepared as described.59
Brieﬂy, cells (2  106/20 ml DMEM/High glucose (4.5 g/L) medium
containing FCS (2%, v/v)) were incubated for 16 h at 37 C, 5% CO2.
The culture mediumwas replaced by fresh medium, interleukin-1b
(1 ng/ml) was added, and cells were incubated for another 72 h.
Then, cells were detached with trypsin/EDTA, washed with PBS
and frozen in liquid nitrogen. Ice-cold homogenization buffer
(0.1 M potassium phosphate buffer pH 7.4, 1 mM phenylmethyl-
sulfonyl ﬂuoride, 60 lg/ml soybean trypsin inhibitor, 1 lg/ml leu-
peptin, 2.5 mM glutathione, and 250 mM sucrose) was added. After
15 min on ice, cells were resuspended and sonicated (3  20 s). The
homogenate was subjected to differential centrifugation (10,000g
for 10 min and at 174,000g for 1 h at 4 C). The pellet (microso-
mal fraction) was resuspended in 1 ml homogenization buffer,
and protein concentration was determined by the Coomassie pro-
tein assay. The microsomal membranes were then diluted in potas-
sium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM
glutathione (100 ll total volume) and test compounds or vehicle
(DMSO) were added. After 15 min, enzymatic PGE2 formation
was initiated by addition of 20 lM PGH2 (ﬁnal concentration).
After 1 min at 4 C, the reaction was terminated with 100 ll of stop
solution (40 mM FeCl2, 80 mM citric acid and 10 lM of 11b-PGE2),
PGE2 was separated by solid phase extraction on reversed phase
(RP)-C18 material using acetonitrile (200 ll) as eluent, and ana-
lyzed by RP-HPLC (30% acetonitrile aqueous + 0.007% TFA (v/v),
Nova-Pak C18 column, 5  100 mm, 4 lm particle size, ﬂow rate
1 ml/min) with UV detection at 195 nm. 11b-PGE2 was used as
internal standard to quantify PGE2 formation.
3. Results and discussion
3.1. Validation of the 2D search query
In brief, various runs showed that the best results were
achieved with ECFP4 ﬁngerprints with a Tanimoto coefﬁcient
P0.25 and a multiple-molecule query consisting of compounds
1, 3, and 4, which represented the most potent and chemically
diverse molecules also later employed in the creation of the phar-
macophore model (Fig. 3).20,25,26 In this combination, a highFigure 3. Training set compoundsenrichment was achieved in the screening experiments using
set_2 (%Y = 48.28, GH = 0.49, EF1% = 67.87, EF0.5% = 121.46).
3.2. Pharmacophore model validation
In order to select the best-performing model for the virtual
screening campaign, the hypotheses were validated thoroughly.
The synthetic compounds 1–4 and the natural product arzanol
(5) from the medicinal plant Helichrysum italicum were selected
as training set (Fig. 3) for pharmacophore modeling.20,25,26,60 We
assigned compound 1 a principal value of 2 (highly active), while
the remaining compounds in the training set 2–5 were assigned
a principal value of 1 (active, Table 1). Furthermore, a different
binding mode was assumed in case of 5, and so the value for
MOF was adjusted to 1, while this value was left unmodiﬁed
among the other compounds in the training set. This adjustment
implies that a ‘partial ﬁt’ of all compounds, except compound 5,
was not allowed during the hypothesis generation process.
Among the 10 computed hypotheses, Hypo01 and Hypo06
showed the most promising results. They returned 35.7% of the
highly active inhibitors, respectively, and 57.1% (Hypo01) or
50.0% (Hypo06) of the medium active inhibitors, while all con-
ﬁrmed inactive molecules were discarded. Accounting in the eval-
uation the Kruskal–Wallis’ statistic, good model quality was
achieved in case of Hypo01 and Hypo06 (Table 2). The differences
between these two most promising 3D pharmacophore models
were quite subtle. Hypo01 consisted of one RA, one HBA, one
HBD, and two Hal, while Hypo06 comprised basically the same fea-
tures, apart from one HYD in the position of the RA. The statistical
evaluation with the post hoc test showed, that in case of Hypo01,
conﬁrmed inactive molecules were separated from medium active
inhibitors (p = 0.0029) and highly active inhibitors (p = 0.0523) by
their geometrical ﬁt score, displaying the best results among all
hypotheses. The results from the screening experiments of set_1
with Hypo01 are available in Supporting information. In thefor pharmacophore modeling.
Table 2
Results from the theoretical validation of the 3D pharmacophore models
%Y GH EF1% EF0.5% Kruskal–Wallis’ statistic p
Hypo01 4.45 0.15 32.14 50.00 9.78 0.0075
Hypo02 1.54 0.12 17.86 35.71 5.04 0.0806
Hypo03 1.55 0.12 17.86 35.71 5.65 0.0593
Hypo04 0.99 0.10 14.29 21.43 5.30 0.0705
Hypo05 0.99 0.10 14.29 14.29 5.30 0.0705
Hypo06 2.36 0.12 25.00 35.71 8.36 0.0153
Hypo07 2.58 0.15 28.57 35.71 5.37 0.0682
Hypo08 1.37 0.16 21.43 42.86 4.89 0.0869
Hypo09 1.58 0.15 39.29 35.71 3.74 0.1538
Hypo10 1.61 0.15 32.14 28.57 2.99 0.2238
Figure 4. Depiction of Hypo01; chemical features are color-coded: light blue-Hal;
orange-RA; magenta-HBD; green-HBA.
Table 3
Summary of results from the experimental evaluation for the four novel molecules,
suppressing mPGES-1 activity, among the 16 tested molecules
Compound Chemical structure Remaining
activity at
10 lM (%)
IC50
(lM)
6 32.78 ± 1.73 4.5
7 34.22 ± 2.56 3.8
8 63.8 ± 6.21 —
9 64.0 ± 2.30 —
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Figure 5. Inhibition of mPGES-1 by compounds 6 and 7. Data are given as
mean ± SEM; n = 3.
S. M. Noha et al. / Bioorg. Med. Chem. 23 (2015) 4839–4845 4843benchmarking experiments, Hypo01 together with Hypo07 to
Hypo10 showed the most promising results when the GH-score
was accounted (GHP0.15). The EF-values prioritized Hypo01
together with Hypo06 to Hypo10. Especially, when EF0.5% was
accounted, Hypo01 outperformed the other hypotheses, while
Hypo01 also attained the best results in terms of%Y. Together,
the results pointed towards superior model quality in case of
Hypo01 (Table 2). Hypo01, the best-performing pharmacophore
model is shown in Figure 4.
3.3. Virtual screening using an external library
Finally, to experimentally validate the virtual screening proto-
col, the Vitas-M library (http://www.vitasmlab.com/) was ﬁltered.
Out of the initial compound library, which comprised 1,305,485
molecules, 1,020,417 molecules (78.2%) and 974,991 molecules
(74.7%) were retrieved in the forward ﬁltering by applying the ﬁl-
ter on the aqueous solubility and the Lipinski and Veber rules,
respectively. Then, out of the compound library which was
returned from these previous ﬁlters, a focused library of 18,057
molecules (1.4%) was retrieved by the application of 2D similarity
screening. Afterwards, pharmacophore-based virtual screening
was performed returning 8079 ﬁtting molecules (0.6% of the initial
Vitas-M library). We only considered molecules for further pro-
cessing, which attained high ﬁt-values (pharmacophore ﬁt P2.5).
This reduced the number of remaining molecules to 1857 (0.14%
of the initial library). To enhance the structural diversity of the hits
to be biologically tested, these molecules were clustered. The 500molecules (0.04% of the Vitas-M collection), retrieved as cluster
centers were submitted to molecular docking. After re-scoring by
molecular docking, the hit-list was visually inspected. Finally, 20
molecules were selected of which 17 were available and acquired
for biological evaluation in the cell-free mPGES-1 activity assay.
Among the tested molecules (10 lM, ﬁnal concentration),
compounds 6 and 7 were revealed as efﬁcient inhibitors of
mPGES-1-mediated PGE2 synthesis (Table 3). Concentration–
response analysis for compounds 6 and 7 revealed IC50 values of
4.5 and 3.8 lM (Fig. 5), potencies that are close to those of the ref-
erence inhibitor MK-886 (IC50 = 2.4 lM) in a comparable test sys-
tem.61 In addition, compounds 8 and 9 signiﬁcantly suppressed
mPGES-1 activity at 10 lM, but less than 50% (Table 3). Thus,
IC50 values were not determined. The other 13 molecules out of
the 17 acquired ones (which are shown in Supporting information)
failed to inhibit mPGES-1 at 10 lM or were not determined.
In order to conﬁrm that the most potent compounds 6 and 7 are
speciﬁc for mPGES-1, we tested on one hand if reduced mPGES-1
Figure 6. (A) Predicted binding modes, shown for the two most active molecules yielded in the virtual screening campaign, compounds 6 (gray) and 7 (magenta). (B) In
comparison, the binding mode of the highly potent inhibitor LVJ is depicted, following the minimization and 3D pharmacophore creation within LigandScout. Glutathione
(GSH); chemical-features are color-coded: red arrow—HBA; green arrow—HBD, yellow sphere—HYD; the poses are shown with receptor-binding surface (color-coded by
aggregated hydrophilicity/hydrophobicity: blue/gray, respectively).
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the other hand, we analyzed if they also affect related enzymes
within the AA cascade. Wash-out experiments revealed reversible
mPGES-1 inhibition (Fig. S1), and triton-X100 failed to abolish the
mPGES-1 inhibitory activity of 6 and 7 (Fig. S2), thus, excluding
unspeciﬁc interference. Moreover, 6 and 7 were poor inhibitors
of isolated COX-2 (IC50 >10 lM, Fig. S3). However, 7 effectively
inhibited 5-lipoxygenase in a cell-free assay with an IC50 value of
about 5 lM, whereas 6 was less active (IC50 >10 lM, Fig. S4).
Note that dual inhibition of mPGES-1 and 5-lipoxygenase is com-
mon to many structural classes of inhibitors of natural synthetic
origin.62 Together, we conclude that 6 and 7 rather speciﬁcally
interact with mPGES-1 and inhibit its activity.
To obtain a more profound insight on potential binding modes,
the virtual screening hits were submitted to molecular docking.
Accounting the docking poses of compounds 6 and 7 (Fig. 6A),
these novel bioactive molecules were predicted to be involved in
hydrogen-bonding to Ser127, which is assumed to serve as a key
residue in the catalytic activity.35 Furthermore, a hydrogen-bond
was predicted to be formed between 6 and Gln36. Interestingly,
both inhibitors were predicted to adopt a conformation, where
these ligands complement the surface of the binding site adjacent
to glutathione. In case of 6, a substituted benzene ring was pre-
dicted to be orientated close to Phe44 and Leu39, which formed
a hydrophobic contact to this ligand moiety. In case of 7, the ben-
zene ring, which was predicted to bind next to Phe44, has a chlo-
rine substituent attached, which could be involved in a
hydrophobic interaction with Leu39. The substituted benzene moi-
eties of 6 and 7, which were oriented towards the opposite site of
the mPGES-1 binding site, were predicted to be embedded in a
hydrophobic site formed by mainly aromatic or hydrophobic
amino acids (e.g., Tyr28, Tyr130, Thr131, Ala31, and Ile32). In com-
parison, LVJ (Fig. 6B), which has inhibitory potency on mPGES-1
activity in the low nanomolar range, adopts a position and orienta-
tion in the binding pocket which is slightly shifted towards mainly
hydrophobic amino acids (e.g., Ala123, Val128, and Leu132), while
several hydrogen-bonds are formed to the key residue Ser127 and
other residues (e.g., Gln36 and His53).4. Discussion
We herein report the discovery of four novel molecules sup-
pressing mPGES-1 activity, of which the two most active ones
showed the desired activity in the low micromolar range. When
only regarding the most active compounds, a hit rate of 12.5%
(two virtual screening hits out of 16 tested molecules) was
achieved. Interestingly, this is comparable to other studies, in
which prospective virtual library screening for the discovery of
novel and non-acidic mPGES-1 inhibitors was conducted. For
instance, He et al. attained good results by employing a molecular
dynamics simulation to obtain an altered conformation of the 3D-
structure of mPGES-1, which was modiﬁed towards an active state
conformation and utilized in a docking-based screening strategy.
Following the in silico approach, 21 molecules of 142 tested mole-
cules showed the desired activity in the experimental evaluation
(hit rate: 14.8%).32 Furthermore, Rörsch et al. applied basically
ligand-based methods in the search for mPGES-1 inhibitors.
Following the experimental evaluation of 17 molecules, three
novel bioactive molecules were discovered and for one of those
an IC50 value was determined, showing that this compound exerts
potency in the sub-micromolar range.29 Fortunately, very recently
the 3D-structure of mPGES-1 with a co-crystallized inhibitor
became available.36 We therefore utilized this 3D-structure in a
docking study of the two most active molecules, yielded in this
study, compounds 6 and 7, in order to surmise binding modes of
these novel mPGES-1 inhibitors. We thereby predicted that these
molecules are accommodated nicely in the site adjacent to the
cofactor glutathione, and could exhibit molecular interactions to
the key residue Ser127. Together, the compounds 6 and 7 showed
inhibitory potency on mPGES-1 activity in the low micromolar
range, making them interesting starting points for optimization
efforts.
Basically, virtual screening techniques are usually validated by
screening (a) validation set(s) in benchmarking experiments. In
cases like this study, where very similar models performwith quite
comparable results, an additional validation with the Kruskal–
Wallis test can be helpful in the selection of the screening model,
S. M. Noha et al. / Bioorg. Med. Chem. 23 (2015) 4839–4845 4845especially as this test is considered to serve as robust investigation
of the model quality.38,39
5. Conclusion
In summary, a multistep virtual screening protocol is presented,
which included a novel concept in the validation of the 3D pharma-
cophore. Following a virtual screening campaign the results of the
experimental evaluation conﬁrmed the protocol quality, while the
two most active molecules which inhibited mPGES-1 in a cell-free
mPGES-1 activity assay, compounds 6 and 7, may serve as promis-
ing starting points for further optimization. The results may be
considered as a case study; however, the modiﬁed concept applied
in the pharmacophore model validation may be useful for further
studies on other targets.
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